Randomized Phase II Trials: A Long-term Investment With Promising Returns

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm

(2010) R. B. Walter et al.   BLOOD

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Other Paradigms

(2010) Walter Stadler   CANCER JOURNAL

Other Paradigms: Better Treatments Are Identified by Better Trials

(2010) Manish R. Sharma et al.   CANCER JOURNAL

Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology

(2010) M. L. Maitland et al.   CLINICAL CANCER RESEARCH

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

(2010) L. Seymour et al.   CLINICAL CANCER RESEARCH

Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

(2010) J. E. Dancey et al.   CLINICAL CANCER RESEARCH

Bayesian adaptive randomization designs for targeted agent development

(2010) J. Jack Lee et al.   Clinical Trials

Randomized Phase II Trials: Inevitable or Inadvisable?

(2010) Hui K. Gan et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trials: Misleading and Unreliable

(2010) David J. Stewart   JOURNAL OF CLINICAL ONCOLOGY

Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research

(2010) David J. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials

(2010) Hui Tang et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

(2010) Philip A. Philip et al.   JOURNAL OF CLINICAL ONCOLOGY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer

(2010) Jennifer S. Temel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase II Designs

(2009) L. Rubinstein et al.   CLINICAL CANCER RESEARCH

Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center

(2009) Swati Biswas et al.   Clinical Trials

Phase II Trials inJournal of Clinical Oncology

(2009) Stephen A. Cannistra   JOURNAL OF CLINICAL ONCOLOGY

The Delayed-Start Study Design

(2009) Ralph B. D'Agostino   NEW ENGLAND JOURNAL OF MEDICINE

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

(2009) C. Warren Olanow et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III

(2008) Robert H. El-Maraghi et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY